{"schema_version":"secwatch.filing_event.v1","accession":"0001599298-26-000076","form_type":"8-K","ticker":"SMMT","cik":"0001599298","company_name":"Summit Therapeutics Inc.","filed_at":"2026-09-03T13:21:44+00:00","discovered_at":"2026-09-03T13:23:05.423387+00:00","generated_at":"2026-09-03T13:23:26.792508+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Summit partner Akeso reports positive OS for ivonescimab in HARMONi-2 vs pembrolizumab","bullets":["Akeso's HARMONi-2: statistically significant OS improvement for ivonescimab vs pembrolizumab in PD-L1-positive advanced NSCLC.","Primary PFS analysis earlier: HR 0.51 (95% CI 0.38-0.69; p<0.0001) by IRRC; OS data to be presented at upcoming medical conference.","Ivonescimab was approved by China's NMPA in April 2025 based on HARMONi-2; Summit holds license rights in US/Europe where it remains investigational.","Summit is conducting HARMONi-7 in PD-L1 high-expressing NSCLC."],"urls":{"canonical":"https://secwatch.observer/filing/0001599298-26-000076","json":"https://secwatch.observer/filing/0001599298-26-000076.json","markdown":"https://secwatch.observer/filing/0001599298-26-000076.md","text":"https://secwatch.observer/filing/0001599298-26-000076.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1599298/000159929826000076/0001599298-26-000076-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1599298/000159929826000076/smmt-20260902.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-03T13:23:26.792508+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}